Foghorn Therapeutics Inc. (FHTX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Foghorn Therapeutics Inc. reported revenue of $30.91M, up 36.8% from the prior year. The company ran a net loss, with a net margin of -240.3%. It held $198.10M in total assets against $306.60M in total liabilities.
Key ratios (FY2025)
-279.5%
Operating margin
-240.3%
Net margin
+36.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.91M | $22.60M | $34.16M | $19.23M | $1.32M | $430.0K | — | — |
| Operating Income | -$86.39M | -$102.68M | -$107.91M | -$117.14M | -$100.73M | -$68.53M | -$51.08M | — |
| Net Income | -$74.28M | -$86.62M | -$98.43M | -$108.88M | -$101.32M | -$68.80M | -$51.13M | — |
| EPS (Diluted) | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 | $-6.23 | — | — |
| Total Assets | $198.10M | $283.98M | $285.92M | $404.88M | $519.77M | $255.59M | $22.34M | — |
| Total Liabilities | $306.60M | $329.51M | $363.11M | $404.77M | $422.90M | $109.41M | $23.81M | — |
| Shareholders' Equity | -$108.50M | -$45.53M | -$77.19M | $112.0K | $96.87M | $146.19M | -$88.02M | -$39.27M |
| Cash & Equivalents | $80.88M | $55.45M | $80.34M | $52.21M | $101.14M | $92.80M | $14.98M | — |
| Operating Cash Flow | -$86.10M | -$100.41M | -$118.11M | $193.61M | -$50.25M | -$31.29M | -$46.34M | — |
| Capital Expenditures | $50.0K | $906.0K | $1.22M | $1.21M | $3.31M | $16.18M | $968.0K | — |
| Shares Outstanding | 56.66M | 55.59M | 42.28M | 41.80M | 41.30M | 36.79M | 4.87M | — |